1. Home
  2. HYPR vs CGTX Comparison

HYPR vs CGTX Comparison

Compare HYPR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

N/A

Current Price

$0.67

Market Cap

82.4M

Sector

Health Care

ML Signal

N/A

CGTX

Cognition Therapeutics Inc.

N/A

Current Price

$0.69

Market Cap

79.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYPR
CGTX
Founded
2014
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.4M
79.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HYPR
CGTX
Price
$0.67
$0.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$2.03
★ $3.33
AVG Volume (30 Days)
★ 893.1K
460.9K
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
23.21
★ 62.79
EPS
N/A
★ N/A
Revenue
★ $13,563,000.00
N/A
Revenue This Year
$49.18
N/A
Revenue Next Year
$29.74
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 5.22
N/A
52 Week Low
$0.70
$0.55
52 Week High
$1.94
$1.83

Technical Indicators

Market Signals
Indicator
HYPR
CGTX
Relative Strength Index (RSI) 37.20 35.29
Support Level $0.70 $0.55
Resistance Level $1.05 $1.18
Average True Range (ATR) 0.04 0.05
MACD -0.00 0.00
Stochastic Oscillator 16.71 37.44

Price Performance

Historical Comparison
HYPR
CGTX

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: